S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 27 of 27

Issue Date	Title / Author(s) / Citation	File
2010-10	Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer Kwak, Eunice L.; Bang, Yung-Jue; Camidge, D. Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Jaenne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, S. Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John New England Journal of Medicine, Vol.363 No.18, pp.1693-1703	DOI
2010-12	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer Ou, Sai-Hong Ignatius; Bazhenova, Lyudmila; Camidge, D. Ross; Solomon, Benjamin J.; Herman, June; Kain, Tatiana; Bang, Yung-Jue; Kwak, Eunice L.; Shaw, Alice T.; Salgia, Ravi; Maki, Robert G.; Clark, Jeffrey W.; Wilner, Keith D.; Iafrate, A. John Journal of Thoracic Oncology, Vol.5 No.12, pp.2044-2046	DOI
2011-10	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross The Lancet Oncology, Vol.12 No.11, pp.1004-1012	DOI
2012-10	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Camidge, D. Ross; Bang, Yung-Jue; Kwak, Eunice L.; Iafrate, A. John; Varella-Garcia, Marileila; Fox, Stephen B.; Riely, Gregory J.; Solomon, Benjamin; Ou, Sai-Hong I.; Kim, Dong-Wan; Salgia, Ravi; Fidias, Panagiotis; Engelman, Jeffrey A.; Gandhi, Leena; Jaenne, Pasi A.; Costa, Daniel B.; Shapiro, Geoffrey I.; LoRusso, Patricia; Ruffner, Katherine; Stephenson, Patricia; Tang, Yiyun; Wilner, Keith; Clark, Jeffrey W.; Shaw, Alice T. The Lancet Oncology, Vol.13 No.10, pp.1011-1019	DOI
2013-06	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Jaenne, Pasi A. New England Journal of Medicine, Vol.368 No.25, pp.2385-2394	DOI
2014-03	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer Shaw, Alice T.; Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S. W.; Felip, Enriqueta; Chow, Laura Q. M.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Lau, Yvonne Y.; Goldwasser, Meredith; Boral, Anthony L.; Engelman, Jeffrey A. New England Journal of Medicine, Vol.370 No.13, pp.1189-1197	DOI
2014-11	Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer Shaw, Alice T.; Ou, Sai-Hong I.; Bang, Yung-Jue; Camidge, D. Ross; Solomon, Benjamin J.; Salgia, Ravi; Riely, Gregory J.; Varella-Garcia, Marileila; Shapiro, Geoffrey I.; Costa, Daniel B.; Doebele, Robert C.; Long Phi Le; Zheng, Zongli; Tan, Weiwei; Stephenson, Patricia; Shreeve, S. Martin; Tye, Lesley M.; Christensen, James G.; Wilner, Keith D.; Clark, Jeffrey W.; Iafrate, A. John New England Journal of Medicine, Vol.371 No.21, pp.1963-1971	DOI
2014-11	Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer Blackhall, Fiona; Kim, Dong-Wan; Besse, Benjamin; Nokihara, Hiroshi; Han, Ji-Youn; Wilner, Keith D.; Reisman, Arlene; Iyer, Shrividya; Hirsh, Vera; Shaw, Alice T. Journal of Thoracic Oncology, Vol.9 No.11, pp.1625-1633	DOI
2015-09	Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma Richly, Heike; Kim, Tae Min; Schuler, Martin; Kim, Dong-Wan; Harrison, Simon J.; Shaw, Alice T.; Boral, Anthony L.; Yovine, Alejandro; Solomon, Benjamin Blood, Vol.126 No.10, pp.1257-1258	DOI
2016-04	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S. W.; Felip, Enriqueta; Chow, Laura Q. M.; Camidge, D. Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J.; Solomon, Benjamin J.; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, Siyu; Szczudlo, Tomasz; Yovine, Alejandro; Shaw, Alice T. The Lancet Oncology, Vol.17 No.4, pp.452-463	DOI
2016-12	Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer Gadgeel, Shirish M.; Shaw, Alice T.; Govindan, Ramaswamy; Gandhi, Leena; Socinski, Mark A.; Camidge, D. Ross; De Petris, Luigi; Kim, Dong-Wan; Chiappori, Alberto; Moro-Sibilot, Denis L.; Duruisseaux, Michael; Crino, Lucio; De Pas, Tommaso; Dansin, Eric; Tessmer, Antje; Yang, James Chih-Hsin; Han, Ji-Youn; Bordogna, Walter; Golding, Sophie; Zeaiter, Ali; Ou, Sai-Hong Ignatius Journal of Clinical Oncology, Vol.34 No.34, pp.4079-4085	DOI
2017-08	Scientific Advances in Thoracic Oncology 2016 Soo, Ross A.; Stone, Emily C. A.; Cummings, K. Michael; Jett, James R.; Field, John K.; Groen, Harry J. M.; Mulshine, James L.; Yatabe, Yasushi; Bubendorf, Lukas; Dacic, Sanja; Rami-Porta, Ramon; Detterbeck, Frank C.; Lim, Eric; Asamura, Hisao; Donington, Jessica; Wakelee, Heather A.; Wu, Yi-Long; Higgins, Kristin; Senan, Suresh; Solomon, Benjamin; Kim, Dong-Wan; Johnson, Melissa; Yang, James C. H.; Sequist, Lecia V.; Shaw, Alice T.; Ahn, Myung-Ju; Costa, Daniel B.; Patel, Jyoti D.; Horn, Leora; Gettinger, Scott; Peters, Solange; Wynes, Murry W.; Faivre-Finn, Corinne; Rudin, Charles M.; Tsao, Anne; Baas, Paul; Kelly, Ronan J.; Leighl, Natasha B.; Scagliotti, Giorgio V.; Gandara, David R.; Hirsch, Fred R.; Spigel, David R. Journal of Thoracic Oncology, Vol.12 No.8, pp.1183-1209	DOI
2017-08	Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer Peters, Solange; Camidge, D. Ross; Shaw, Alice T.; Gadgeel, Shirish; Ahn, Jin S.; Kim, Dong-Wan; Ou, Sai-Hong I.; Perol, Maurice; Dziadziuszko, Rafal; Rosell, Rafael; Zeaiter, Ali; Mitry, Emmanuel; Golding, Sophie; Balas, Bogdana; Noe, Johannes; Morcos, Peter N.; Mok, Tony New England Journal of Medicine, Vol.377 No.9, pp.829-838	DOI
2017-08	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive nonsmall- cell lung cancer Blackhall, Fiona; Camidge, D. Ross; Shaw, Alice T.; Soria, Jean-Charles; Solomon, Benjamin J.; Mok, Tony; Hirsh, Vera; Jaenne, Pasi A.; Shi, Yuankai; Yang, Pan-Chyr; De Pas, Tommaso; Hida, Toyoaki; Carpeno, Javier De Castro; Lanzalone, Silvana; Polli, Anna; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Kim, Dong-Wan Esmo Open, Vol.2 No.3, p. e000219	DOI
2017-09	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria Gandhi, Leena; Ou, Sai-Hong Ignatius; Shaw, Alice T.; Barlesi, Fabrice; Dingemans, Anne-Marie C.; Kim, Dong-Wan; Camidge, D. Ross; Hughes, Brett G. M.; Yang, James C. -H.; de Castro, Javier; Crino, Lucio; Lena, Herve; Do, Pascal; Golding, Sophie; Bordogna, Walter; Zeaiter, Ali; Kotb, Ahmed; Gadgeel, Shirish European Journal of Cancer, Vol.82, pp.27-33	DOI
2017-10	Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer Yang, James Chih-Hsin; Ou, Sai-Hong Ignatius; De Petris, Luigi; Gadgeel, Shirish; Gandhi, Leena; Kim, Dong-Wan; Barlesi, Fabrice; Govindan, Ramaswamy; Dingemans, Anne-Marie C.; Crino, Lucio; Lena, Nerve; Popat, Sanjay; Ahn, Jin Seok; Dansin, Eric; Golding, Sophie; Bordogna, Walter; Batas, Bogdana; Morcos, Peter N.; Zeaiter, Ali; Shaw, Alice T. Journal of Thoracic Oncology, Vol.12 No.10, pp.1552-1560	DOI
2018-01	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC Gadgeel, Shirish; Shaw, Alice T.; Barlesi, Fabrice; Crino, Lucio; Yang, James Chih-Hsin; Dingemans, Anne-Marie C.; Kim, Dong-Wan; de Marinis, Filippo; Schulz, Mathias; Liu, Shiyao; Gupta, Ravindra; Kotb, Ahmed; Ou, Sai-Hong Ignatius British Journal of Cancer, Vol.118 No.1, pp.38-42	DOI
2018-07	Crizotinib versus chemotherapy in asian patients with alk-positive advanced non-small cell lung cancer Nishio, Makoto; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Solomon, Benjamin J.; Shaw, Alice T.; Hashigaki, Satoshi; Ohki, Emiko; Usari, Tiziana; Paolini, Jolanda; Polli, Anna; Wilner, Keith D.; Mok, Tony Cancer Research and Treatment, Vol.50 No.3, pp.691-700	view file DOI
2018-09	Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials Camidge, D. Ross; Kim, Dong-Wan; Tiseo, Marcello; Langer, Corey J.; Ahn, Myung-Ju; Shaw, Alice T.; Huber, Rudolf M.; Hochmair, Maximilian J.; Lee, Dae Ho; Bazhenova, Lyudmila A.; Gold, Kathryn A.; Ou, Sai-Hong Ignatius; West, Howard L.; Reichmann, William; Haney, Jeff; Clackson, Tim; Kerstein, David; Gettinger, Scott N. Journal of Clinical Oncology, Vol.36 No.26, pp.2693-2701	DOI
2018-10	Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibit ROS1/TRK/ALK solvent-front mutations Drilon, Alexander; Ou, Sai-Hong Ignatius; Cho, Byoung Chul; Kim, Dong-Wan; Lees, Jeeyun; Lin, Jessica J.; Zhu, Viola W.; Ahns, Myung-Ju; Camidge, D. Ross; Nguyen, Judy; Zhai, Dayong; Deng, Wei; Huang, Zhongdong; Rogers, Evan; Liu, Juliet; Whitten, Jeff; Lim, John K.; Stopatschinskaja, Shanna; Hyman, David M.; Doebele, Robert C.; Cui, J. Jean; Shaw, Alice T. Cancer Discovery, Vol.8 No.10, pp.1227-1236	DOI
2019-11	Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies Gadgeel, Shirish; Shaw, Alice T.; Barlesi, Fabrice; Crino, Lucio; Yang, James C. H.; Dingemans, Anne-Marie; Kim, Dong-Wan; de Marinis, Filippo; Schulz, Mathias; Liu, Shiyao; Gupta, Ravindra; Smoljanovic, Vlatka; Ou, Sai-Hong Ignatius Lung Cancer: Targets and Therapy, Vol.10, pp.125-130	view file DOI
2020-01	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer Ou, Sai-Hong Ignatius; Gadgeel, Shirish M.; Barlesi, Fabrice; Yang, James Chih-Hsin; De Petris, Luigi; Kim, Dong-Wan; Govindan, Ramaswamy; Dingemans, Anne-Marie; Crino, Lucio; Lena, Herve; Popat, Sanjay; Ahn, Jin Seok; Dansin, Eric; Mitry, Emmanuel; Mueller, Barbara; Bordogna, Walter; Balas, Bogdana; Morcos, Peter N.; Shaw, Alice T. Lung Cancer, Vol.139, pp.22-27	DOI
2020-11	First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer Shaw, Alice T.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Liu, Geoffrey; Mazieres, Julien; Kim, Dong-Wan; Mok, Tony; Polli, Anna; Thurm, Holger; Calella, Anna M.; Peltz, Gerson; Solomon, Benjamin J. New England Journal of Medicine, Vol.383 No.21, pp.2018-2029	DOI
2021-02	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study Mok, Tony; Peters, Solange; Camidge, D. Ross; Noe, Johannes; Gadgeel, Shirish; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Konopa, Krzysztof; Pozzi, Emanuela; Liu, Ting; Loftin, Isabell R.; Williams, Crystal; Shaw, Alice T. Journal of Thoracic Oncology, Vol.16 No.2, pp.259-268	DOI
2021-08	Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer Solomon, Benjamin J.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Liu, Geoffrey; Mazieres, Julien; Kim, Dong-Wan; Mok, Tony; Polli, Anna; Thurm, Holger; Calella, Anna Maria; Peltz, Gerson; Shaw, Alice T. Future Oncology, Vol.17 No.34, pp.4649-4656	DOI
2022-12	Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer Mazieres, Julien; Iadeluca, Laura; Shaw, Alice T.; Solomon, Benjamin J.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Kim, Dong-Wan; Mok, Tony; Reisman, Arlene; Thurm, Holger; Polli, Anna M.; Liu, Geoffrey Lung Cancer, Vol.174, pp.146-156	DOI
	Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer Chen, Joseph; Bearz, Alessandra; Kim, Dong-Wan; Mamdani, Hirva; Bauman, Jessica; Chiari, Rita; Ou, Sai-Hong Ignatius; Solomon, Benjamin J.; Soo, Ross A.; Felip, Enriqueta; Shaw, Alice T.; Thurm, Holger; Clancy, Jill S.; Lee, Kimberly; O'Gorman, Melissa; Tanski, Cherie; Pithavala, Yazdi K. Clinical Pharmacokinetics, Vol.63 No.2, pp.171-182	DOI